The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide.

SparkCures ID	1096
Trial Phase	Phase 1
Enrollment	18 Patients
Treatments	CYAD-211 Cyclophosphamide Fludarabine
Tags	B-Cell Maturation Antigen (BCMA) CAR T Cell (Allogeneic)
Trial Sponsors	Celyad Therapeutics
NCT Identifier	NCT04613557

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

Documented diagnosis of MM with relapsed or refractory disease to at least two prior MM treatment regimens which should include exposure to IMiD and PIs either alone or in combination.
Presence of measurable disease as per International Myeloma Working Group (IMWG) Response Criteria
Eastern Cooperative Oncology Group (ECOG) below or equal 2
Adequate hematologic, renal, hepatic, pulmonary, and cardiac function

Exclusion Criteria:

History or presence of clinically relevant central nervous system (CNS) tumor involement.
Autologous stem cell transplant within 12 weeks of registration or an allogeneic stem cell transplant within 6 months of starting study treatment.
Any investigational agent within 3 weeks prior to the initiation of the non-myeloablative preconditioning chemotherapy).
Prior systemic therapy for MM within 14 days prior to the initiation of the non-myeloablative preconditioning chemotherapy.
Prior treatment with any BCMA-targeted therapy and which has not achieved at least a partial response.

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Overview

Am I Eligible?

US Trial Locations

Trial Links

First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy